公司新闻
更多>>公司公告
更多>>- 12/22ASTRAZENECA PLC--Director/PDMR Shareholding
- 12/22ASTRAZENECA PLC--Update on LATIFY Phase III trial of ceralasertib
- 12/22ASTRAZENECA PLC--Enhertu granted BTD for post-neoadjuvant early BC
- 12/16ASTRAZENECA PLC--Enhertu approved in US for 1L HER2 metastatic BC
- 12/16ASTRAZENECA PLC--Subcutaneous Saphnelo approved in EU
- 12/04ASTRAZENECA PLC--Holding(s) in Company
- 12/01ASTRAZENECA PLC--Block listing Interim Review
- 11/26ASTRAZENECA PLC--Imfinzi approved in US for early gastric cancer
- 11/24ASTRAZENECA PLC--AstraZeneca manufacturing investment in Maryland
- 11/06ASTRAZENECA PLC--9M and Q3 2025 results
- 10/20AstraZeneca PLC--US FDA Approves Tezspire in CRSwNP
- 11/17ASTRAZENECA PLC--Holding(s) in Company
- 09/01AstraZeneca PLC--Total Voting Rights
- 11/14ASTRAZENECA PLC--Director/PDMR Shareholding